Abstract: It is an object of the present invention to provide a transmission-blocking vaccine using an immunogenic protein which is specifically expressed in the oocyst stage of malaria parasites or a peptide fragment thereof, and an oral transmission-blocking vaccine capable of immunizing various animals involved in the malaria infectious cycle with such a vaccine. The present invention relates to a malaria transmission-blocking vaccine for oral administration containing an immunogenic protein derived from malaria parasite which is specifically expressed in the oocyst stage of malaria parasites or a peptide fragment thereof, and a method of blocking the transmission of malaria using the same.

Abstract: It is an object of the present invention to provide a transmission-blocking vaccine using an immunogenic protein which is specifically expressed in the oocyst stage of malaria parasites or a peptide fragment thereof, and an oral transmission-blocking vaccine capable of immunizing various animals involved in the malaria infectious cycle with such a vaccine. The present invention relates to a malaria transmission-blocking vaccine for oral administration containing an immunogenic protein derived from malaria parasite which is specifically expressed in the oocyst stage of malaria parasites or a peptide fragment thereof, and a method of blocking the transmission of malaria using the same.

Abstract: The object of the present invention is to provide a therapeutic agent illustrating an immediate and sustained effect on chronic intractable external otitis. The present invention provide a composition, pharmaceutical composition, food and feed for preventing and/or treating chronic intractable external otitis, each comprising interferon-? (IFN?) as an active ingredient. Orally administering the composition of the present invention can provide inhibition, alleviation, treatment and prevention for chronic intractable external otitis. According to the present invention, IFN? can give a sufficient effect even when administered in a very small amount.

Abstract: The object of the present invention is to provide a therapeutic agent illustrating an immediate and sustained effect on chronic intractable external otitis. The present invention provide a composition, pharmaceutical composition, food and feed for preventing and/or treating chronic intractable external otitis, each comprising interferon-? (IFN?) as an active ingredient. Orally administering the composition of the present invention can provide inhibition, alleviation, treatment and prevention for chronic intractable external otitis. According to the present invention, IFN? can give a sufficient effect even when administered in a very small amount.

Abstract: The present invention provides an agent for controlling Escherichia coli diarrhea comprising a Shiga toxin as an active ingredient.

Abstract: The present invention provides an agent for controlling Escherichia coli diarrhea comprising a Shiga toxin as an active ingredient.

Abstract: The present invention provides oral compositions which contain interferon ? (IFN?) as an active ingredient for preventing and/or treating periodontal disease. The number of causative microorganisms of periodontal disease can be suppressed by administering the compositions into the oral cavity. IFN? of the present invention can produce a sufficient effect even when administered at a very low dose. Furthermore, the compositions of the present invention can also be readily administered to animals such as dogs by formulating them into feed or such.

Abstract: The present invention provides oral compositions which contain interferon ? (IFN?) as an active ingredient for preventing and/or treating periodontal disease. The number of causative microorganisms of periodontal disease can be suppressed by administering the compositions into the oral cavity. IFN? of the present invention can produce a sufficient effect even when administered at a very low dose. Furthermore, the compositions of the present invention can also be readily administered to animals such as dogs by formulating them into feed or such.

Abstract: Disclosed is a technique that facilitates the oral ingestion of adiponectin in a large quantity and enables the expansion of the range of use applications of adiponectin. Specifically disclosed is an appetite control agent for oral administration, which comprises adiponectin as an active ingredient. Particularly, the appetite control agent comprises a transformant capable of expressing adiponectin. Also specifically disclosed is a food composition for controlling appetite, which comprises the appetite control agent.

Abstract: The present invention provides oral compositions which contain interferon ? (IFN?) as an active ingredient for preventing and/or treating periodontal disease. The number of causative microorganisms of periodontal disease can be suppressed by administering the compositions into the oral cavity. IFN? of the present invention can produce a sufficient effect even when administered at a very low dose. Furthermore, the compositions of the present invention can also be readily administered to animals such as dogs by formulating them into feed or such.

Abstract: A method of reducing the contamination amount of mycotoxin in cereals wherein one or more compounds A selected from the group consisting of ammonium salts, primary to quaternary ammonium salts, alkali metal salts, alkaline earth metal salts and polyvalent metal salts of phosphorous acid and phosphite ester are given to the cereals.

Abstract: A method of reducing the contamination amount of mycotoxin in cereals wherein one or more compounds A selected from the group consisting of ammonium salts, primary to quaternary ammonium salts, alkali metal salts, alkaline earth metal salts and polyvalent metal salts of phosphorous acid and phosphite ester are given to the cereals.

Abstract: We search for a cultivation method for reducing the amount of mycotoxin contamination in wheat which has been an important pending question for the quality in actual producing field of wheat and the health hazard risk for customers. The present invention discloses a method of reducing the contamination amount of mycotoxin in cereals characterized in that one or more compounds A selected from the group consisting of ammonium salts, primary to quaternary ammonium salts, alkali metal salts, alkaline earth metal salts and polyvalent metal salts of phosphorous acid and phosphite ester are given to the cereals.

Abstract: Disclosed is a technique that facilitates the oral ingestion of adiponectin in a large quantity and enables the expansion of the range of use applications of adiponectin. Specifically disclosed is an appetite control agent for oral administration, which comprises adiponectin as an active ingredient. Particularly, the appetite control agent comprises a transformant capable of expressing adiponectin. Also specifically disclosed is a food composition for controlling appetite, which comprises the appetite control agent.